With an aim to develop improved infrastructure and networking
tools for the interpretation and reporting of genetic sequencing
), a major developer of life science tools for large-scale genetic
analysis, formed a strategic association with Partners HealthCare,
a healthcare system developed by Brigham and Women's Hospital and
Massachusetts General Hospital.
These tools will combine the functionality of Illumina's MiSeq
sequencing system and Partners' GeneInsight Suite (an IT platform
used to streamline the processing of complex genetic test results)
in order to develop the base for a comprehensive sequencing and
clinically relevant reporting solution.
This combined MiSeq-GeneInsight solution will connect Illumina's
BaseSpace cloud computing platform and MyGenome app for iPad, with
a clinical lab's local laboratory information system (LIS).
Illumina claims that this solution will create smooth workflow
starting on MiSeq and delivering results directly into the
GeneInsight tool providing accurate data interpretation. The
company expects this collaboration to create a new standard in Next
Generation sequencing (NGS) in clinical-based applications.
At the start, both the companies intend to release the
integrated tool to a limited number of pilot customers in pilot
sites like a selected group of reference laboratories within
leading academic institutions, molecular and genetic pathology
laboratories and commercial reference laboratories. Illumina will
also use the GeneInsight Lab application in its CLIA-certified
sequencing laboratory to support the operation.
Illumina made significant developments in its MiSeq platform.
The company expects to submit the MiSeq platform to the FDA for
510(k) approval before 2012 end. Recently, the company launched
TruSight content sets for targeted sequencing, designed for use in
NGS. Earlier in March, the company launched TruSeq Amplicon, a
cancer panel for MiSeq system to aid researchers in the
identification of the sequence of cancer loci. This is significant
since it makes sequencing possible even in difficult samples such
as formalin-fixed, paraffin embedded ("FFPE") tumor samples.
The company also entered into a partnership with Siemens
Healthcare Diagnostics to use the MiSeq platform for Siemens'
molecular HIV tests. Furthermore, the company expanded its Genome
Network with the inclusion of the British Columbia Cancer Agency to
its existing list. Illumina experiences tough competition from
Thermo Fisher Scientific
), among others.
Currently, Illumina retains a short-term Zacks #3 Rank (Hold).
Over the long term, we have a 'Neutral' recommendation on the
ILLUMINA INC (ILMN): Free Stock Analysis Report
LIFE TECHNOLOGS (LIFE): Free Stock Analysis
THERMO FISHER (TMO): Free Stock Analysis Report
To read this article on Zacks.com click here.